
The US fertility provider, CCRM Fertility, has announced the acquisition of The Institute for Reproductive Medicine & Science (IRMS).
With the new addition of IRMS, the fertility company will now serve 11 major metropolitan areas with 34 locations across the US and Canada.
Jon Pardew, president and CEO of CCRM Fertility, said the acquisition is just one piece to the company’s overall growth strategy, further strengthening its commitment to its patients, physicians, technologies, fertility care and research.
“Bringing IRMS into our family made perfect sense,” he added. “It has a longstanding reputation for world-class services, personalised fertility treatment and access to care through convenient locations.
“We are confident IRMS’s diverse and experienced team of physicians and embryologists will be an excellent addition to the CCRM Fertility team. Our combined commitment to quality care and innovative solutions now makes us one of the largest and most advanced network of fertility clinics servicing North America.”
The IRMS clinical director, Dr Debbra Keegan, said: “The IRMS team is incredibly excited to join the CCRM Fertility network as we expand our philosophy of care throughout the State of New Jersey and beyond.
“We chose CCRM Fertility because of our common commitment to patient-centric care, best practices in medicine and scientific expertise. We look forward to this partnership bringing yet another level of superior reproductive care to our valuable patients.”
CCRM Fertility specialises in fertility treatments, IVF, fertility testing, fertility preservation, genetic testing, third-party reproduction and egg donation.
The addition of IRMS will combine the two companies’ scientific advances, laboratory techniques and full suite of reproductive services.
The acquisition comes weeks after the fertility provider announced the expansion of its partnership with TMRW Life Sciences, the world’s first automated platform for the management and care of the frozen eggs and embryos used in IVF.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









